临床试验中局部研究者与中心裁决者对糜烂性食管炎洛杉矶分级评分的比较
约30%的典型胃食管反流病(GERD)症状患者有糜烂性食管炎(EE)的内镜证据。EE严重程度常用洛杉矶(LA)分级系统评估。几乎所有EE治疗研究仅依赖局部研究者分级,而vonoprazan对比兰索拉唑治疗EE的III期临床试验(NCT04124926)强制要求中心裁决内镜分级。本研究旨在评估该试验筛选入组时局部研究者与中心裁决者对EE分级的一致性。
要点
- 约30%的典型GERD症状患者有EE的内镜证据。
- EE严重程度常用LA分级系统评估。
- vonoprazan对比兰索拉唑的III期临床试验强制要求中心裁决内镜分级。
核心结论
- 本研究评估了vonoprazan对比兰索拉唑治疗EE的III期临床试验筛选期间局部研究者与中心裁决者EE分级的一致性。
研究设计与样本
- 研究基于vonoprazan对比兰索拉唑治疗EE的III期临床试验(NCT04124926)的筛选数据,评估局部研究者与中心裁决者EE分级的一致性。
主要发现
- 原文未报告具体一致性数值。
关键数值与推荐
- EE严重程度采用LA分级系统,从A级(轻微)到D级(非常严重),依据内镜下可见黏膜破损的范围。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Approximately 30% of patients with typical gastroesophageal reflux disease (GERD) symptoms have endoscopic evidence of erosive esophagitis (EE).1 The severity of EE is commonly graded using the Los Angeles (LA) classification system as grade A (minimal) to D (very severe), depending on the extent of endoscopically visible mucosal breaks (Supplementary Figure 1).2 Accurate grading of EE severity is crucial in clinical trials of medical EE treatments, as EE severity strongly influences both initial rates of healing and the likelihood of recurrence during maintenance treatment.3,4 Almost all EE treatment studies have relied exclusively on local investigators' grading of EE severity to determine study eligibility and response to treatment. Those few studies that included central adjudication did not assess the reliability of grading by local investigators.5 Unlike typical studies of EE treatment, the phase III clinical trial of vonoprazan versus lansoprazole for the treatment of EE (NCT04124926) mandated central adjudication of endoscopic grading for study participation.6 The aim of the present investigation was to evaluate the rate of agreement between local investigators and central adjudicators for EE grading during screening for entrance into that clinical trial.
引用
- Spechler SJ, Laine L, DeVault KR, et al. Comparison of Los Angeles Grades of Erosive Esophagitis Scored by Local Investigators vs Central Adjudicators in a Clinical Trial. Clin Gastroenterol Hepatol. 2024. PMID: 38777170. doi:10.1016/j.cgh.2024.05.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。